Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913 Phase 1 Study in Combination With FOLFOX and Bevacizumab or Cetuximab for Unresectable Colorectal Cancer
jRCT2051210038Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab and nivolumab in colorectal cancer (CRC), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and Safety. Started Sep 2021; status: active, not recruiting.
02
Drugs
magrolimabnivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2051210038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210038.